CRDL — Cardiol Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$168.66m
- CA$133.90m
- 21
- 11
- 89
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.079 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 14.1 | 20.7 | 38.7 | 41.3 | 29.8 |
Operating Profit | -14.1 | -20.7 | -38.7 | -41.3 | -29.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.7 | -20.6 | -31.6 | -30.9 | -28.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.7 | -20.6 | -31.6 | -30.9 | -28.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.7 | -20.6 | -31.6 | -30.9 | -28.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.7 | -20.6 | -31.6 | -30.9 | -28.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.53 | -0.691 | -0.732 | -0.495 | -0.436 |